Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx

Brief Summary:

• GoodRx is expanding access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron)
• Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx
• GoodRx is also offering self-pay pricing for Zepbound® (tirzepatide) KwikPen® starting at $299 per month
• Foundayo and Zepbound KwikPen are available through GoodRx’s nationwide pharmacy network
• GoodRx is helping pharmaceutical manufacturers deliver consumer-direct pricing at scale from day one

SANTA MONICA, Calif.--(BUSINESS WIRE)--Apr. 9, 2026-- GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron). Eligible self-pay patients can access Foundayo through GoodRx at a starting price of $149 per month, in line with the lowest available discounted cash price at launch. The offering provides transparent pricing and nationwide pharmacy access for the highly anticipated weight management treatment.

GoodRx is also expanding access to Zepbound® (tirzepatide) KwikPen®, available to eligible self-pay patients starting at $299 per month at more than 70,000 pharmacies nationwide. Together with the launch of Foundayo, these offerings expand access to both oral and injectable GLP-1 treatments for adults seeking prescribed obesity care outside traditional insurance pathways.

“We’re excited to work with Lilly to help bring one of the most anticipated innovations in weight management to patients,” said Wendy Barnes, President and CEO of GoodRx. “As new GLP-1 therapies continue to expand, including oral options like Foundayo, it is critical that access evolves alongside innovation. By pairing transparent cash pricing with nationwide pharmacy access and integrated care, we are helping ensure more people understand their options and more easily start treatment.”

“The launch of Foundayo reflects Lilly’s continued commitment to expanding treatment options for people living with obesity and advancing meaningful innovation in this category,” said Laura Steele, Group Vice President of U.S. Cardiometabolic Health at Eli Lilly and Company. “We're committed to expanding access to treatment options through channels that meet patients where they are in their journey.”

Supporting New Access Models for Drug Launches

GoodRx’s role in expanding access to Foundayo reflects a broader shift in how innovative therapies reach patients. For many medications, particularly GLP-1 treatments prescribed for weight loss, insurance coverage remains inconsistent or unavailable, prompting manufacturers to explore new direct-to-consumer access models. GoodRx supports this shift by combining transparent discounted cash pricing, nationwide pharmacy access, and a trusted consumer platform that helps patients start treatment while maintaining continuity of care and the ability to fill prescriptions at their pharmacy of choice.

About GoodRx

GoodRx is the leading platform for medication savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications.

​GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com . We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

GoodRx Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of Foundayo (orforglipron), Zepbound (tirzepatide) KwikPen and related pricing; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260409583467/en/

Media Contact
press@goodrx.com

Source: GoodRx